Intermediate AMD Therapeutics Market Size in the 7MM was ~USD 990 Million in 2023, is expected to grow by 2034, and estimates DelveInsight

DelveInsight's " Intermediate AMD Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of intermediate AMD, historical and forecasted epidemiology as well as the intermediate AMD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Intermediate AMD Market with DelveInsight's In-Depth Report @ Intermediate AMD Market Size [https://www.delveinsight.com/sample-request/intermediate-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Facts and Analysis of the Intermediate AMD Market Report

* Among the 7MM, the US accounted for the highest prevalent cases of intermediate AMD in 2023, with around 19,861,500 cases, these cases are expected to increase during the forecast period.
* Among EU4 and the UK, the total prevalent cases of intermediate AMD were maximum in Germany, while the lowest number of cases were in Spain in 2023.
* According to the estimates, in Japan, it is observed that intermediate AMD was most prevalent in the 65-84 years age group, accounting for over 45% of total cases in 2023.
* The leading Intermediate AMD Companies such as Novartis, Allegro Ophthalmics , and others.
* Promising Intermediate AMD Therapies such as Iptacopan (LNP023), Ranibizumab, and Risuteganib (ALG-1001) and others.

Navigate the complexities of the Intermediate AMD Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Intermediate AMD Market Forecast. Click here to get more insights @ Intermediate AMD Treatment Market [https://www.delveinsight.com/sample-request/intermediate-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Intermediate AMD Epidemiology Segmentation in the 7MM

* Total Intermediate AMD Prevalent Cases
* Total Intermediate AMD Diagnosed Prevalent Cases
* Intermediate AMD Age-specific Cases

Download the report to understand which factors are driving Intermediate AMD epidemiology trends @ Intermediate AMD Prevalence [https://www.delveinsight.com/sample-request/intermediate-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Intermediate AMD Emerging Drugs Profile

* Iptacopan (LNP023): Novartis

Novartis Pharmaceuticals is developing Iptacopan, an oral small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, FB inhibitor LNP023 binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as intermediate age-related macular degeneration (iAMD), C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), etc. Recently, in December 2023, the US FDA approved FABHALTA (ipatocan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH). Currently, the company is investigating iptacopan in the Phase II trial (NCT05230537) for the treatment of patients with early and intermediate age-related macular degeneration.

* Risuteganib (ALG-1001): Allegro Ophthalmics

Allegro Ophthalmics is developing risuteganib (also known as ALG-1001), a breakthrough integrin-regulating therapy for ocular health that reduces mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib helps reduce the cellular burden of oxidative stress and restores retinal homeostasis. Research suggests that risuteganib interferes with integrin functions that have been implicated in retinal diseases, giving it the potential for a broad-spectrum effect on different pathways of oxidative stress. Currently, the company has received the US FDA agreement under Special Protocol Assessment (SPA) for Phase IIb/III clinical trial of risuteganib for the treatment of intermediate, non-exudative age-related macular degeneration (dry AMD). Moreover, the overall protocol design of Phase IIb/III dry AMD clinical trial was finalized by the US FDA.

Intermediate AMD Drugs Market Insights

Integrin inhibitor have been effective in several preclinical models, and promising results have been reported thus far from clinical trials. Indeed, most of the current avSs3 clinical investigations centre on treating eye diseases (age-related macular degeneration (AMD) using topically dosed or intravitreally injected small molecules and peptides, although these molecules also inhibit other av integrins and/or a5Ss1 to varying degrees. The molecules that have progressed the furthest in the clinic are risuteganib (Luminate, Allegro Ophthalmics). It is a small peptide integrin regulator protecting cells of the human RPE against dysfunction related to oxidative stress. With age, decreased mitochondrial oxidative phosphorylation increases the generation of reactive oxygen species and decreased metabolic activity, thus negatively affecting cellular bioenergetics and mitochondrial functioning. It is also known that RPE mitochondrial dysfunction contributes to the oxidative stress causing AMD.

Get In-Depth Knowledge on Intermediate AMD Market Trends and Forecasts with DelveInsight @ Intermediate AMD Treatment Market [https://www.delveinsight.com/sample-request/intermediate-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Intermediate AMD Market Outlook

Intermediate AMD often presents with minimal symptoms, typically involving distorted vision or central visual field loss. Notably, rod recovery time after a bright flash is considerably more prolonged in AMD eyes, especially in the presence of reticular pseudodrusen. The therapeutic landscape of intermediate AMD is devoid of any approved treatment, and to manage this indication, there is a substantial unmet need for therapy to slow its worsening. The pathophysiology of dry AMD is poorly understood. However, there are chances of failure to reach the primary outcomes that might be linked to the advanced stage of the disease rather than a lack of action on appropriate targets. The lack of standardization and validation of related clinical trial endpoints remains an issue. Various composite measures have been used, but there is no gold standard. Composite endpoints and combined outcome measures are being increasingly used in longitudinal and interventional studies. There is no consensus on the best approach to implement combined endpoints in clinical trials on intermediate AMD, and further analysis is needed in this area as well. Current tests do not detect all of the sight problems experienced by people with earlier stages of the disease (e.g., iAMD). Furthermore, there is currently no way to identify which patients with iAMD are at greatest risk of progressing toward advanced AMD. Only few key players are active in the pipeline such as Novartis and Allegro Ophthalmics for the treatment of intermediate AMD.

Scope of the Intermediate AMD Market Report

* Study Period: 2020-2034
* Coverage: 7MM
* Intermediate AMD Companies: Novartis, Allegro Ophthalmics, and others.
* Intermediate AMD Therapies: Iptacopan (LNP023), Ranibizumab, and Risuteganib (ALG-1001), and others.
* Intermediate AMD Therapeutic Assessment: Intermediate AMD current marketed and Intermediate AMD emerging therapies
* Intermediate AMD Market Dynamics: Intermediate AMD market drivers and Intermediate AMD market barriers.
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Intermediate AMD Unmet Needs, KOL's views, Analyst's views, Intermediate AMD Market Access and Reimbursement

Gain a strategic edge in the Intermediate AMD Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Intermediate AMD Market Forecast. Click here to lead in advancements @ Intermediate AMD Clinical Trials Assessment [https://www.delveinsight.com/sample-request/intermediate-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

1. Intermediate AMD Market Report Introduction

2. Executive Summary for Intermediate AMD

3. SWOT analysis of Intermediate AMD

4. Intermediate AMD Patient Share (%) Overview at a Glance

5. Intermediate AMD Market Overview at a Glance

6. Intermediate AMD Disease Background and Overview

7. Intermediate AMD Epidemiology and Patient Population

8. Country-Specific Patient Population of Intermediate AMD

9. Intermediate AMD Current Treatment and Medical Practices

10. Intermediate AMD Unmet Needs

11. Intermediate AMD Emerging Therapies

12. Intermediate AMD Market Outlook

13. Country-Wise Intermediate AMD Market Analysis (2020-2034)

14. Intermediate AMD Market Access and Reimbursement of Therapies

15. Intermediate AMD Market Drivers

16. Intermediate AMD Market Barriers

17. Intermediate AMD Appendix

18. Intermediate AMD Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=intermediate-amd-therapeutics-market-size-in-the-7mm-was-usd-990-million-in-2023-is-expected-to-grow-by-2034-and-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.